Marketing’s Untapped Opportunity in the Medical Product Lifecycle
If marketing’s participation isn't already incorporated into a company's official product development process, they’re missing the boat.
Continuous Process Improvement: The Secret to Navigating Early-Phase Drug Development
Deploying a robust continuous improvement methodology is especially beneficial in the earliest phases of drug development. It can help ensure the delivery of high-quality, reliable, timely bioanalytical and clinical data to make informed decisions about either moving on to the next drug development milestone or pivoting to another strategy.
presented by
The 5 Best Software to Buy for Managing a Spa Franchise
Choosing the right software translates directly into better client management, operational efficiency and growth for your spa franchise. Discover which tool is best for your business.
Data Clean Rooms: The Secret to Secure Healthcare Data Sharing
They allow organizations to break down industry-wide data silos and share data with research partners while maximizing compliance and confidentiality. With the right mindset and implementation, this tech could unlock enormous value for healthcare R&D.
The AI Advantage: Reimagining the Future of Drug Development
Like any other tool, understanding the right problem to apply it to is the difference between success and failure. Addressing a problem is never just about technology; it’s always about people, processes, and technology.
RNA Foundation Models to Improve Pharma R&D Productivity
As RNA biology and RNA therapeutics emerge in the mainstream of pharma, RNA foundation models offer massive potential for revolutionizing R&D.
Balancing Risk and Opportunity to Choose Winning Therapies
The ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.
Take the 2025 Benefit Consultant Sentiment Index Survey
If you’re helping clients navigate big changes—from the surge in GLP-1 demand to AI to the growing pressure to demonstrate ROI – we want your thoughts.
Bridging the Impact Gap in Cancer R&D
It is critical that we rightsize and redistribute available funds based on our knowledge of persistent cancer disparities to help more patients benefit from potentially lifesaving innovations and ensure no one is left behind.
Pharma Returns Slump as Post-Pandemic Realities Set In, Deloitte Report Says
R&D spending rose in response to Covid-19, bringing with it higher expectations for returns on all biopharma investments. The once sky-high projections are coming down to Earth, with returns now in line with pre-pandemic levels, according to a new Deloitte report.
J&J CEO: Our R&D Infrastructure Helps Us Maintain Innovation Amid an Uncertain Economy
Johnson & Johnson's CEO believes the company will maintain its strong reputation for innovation amid changing economic conditions because of its hefty investments in research and development. He said it's crucial to invest both internally and externally, as some of the most innovative and lucrative opportunities come from outside companies.
The new paradigm in drug development: Why platform technology is the solution patients and payers need
The model of investing huge amounts of money into one drug to try to recoup it later is problematic at best and unsustainable at worst. Platform technology provides a better, more cost-effective way forward.
presented by
Everything You Need to Know About Sterilization Cases and Their Role in Healthcare
Innovative sterilization cases and trays are instrumental in reducing infection risk in medical settings. Learn notable things about them and their makers.
INVEST Precision Medicine Conference Video: Software Supporting Biopharma R&D
This panel explores some of the diverse approaches companies are taking to improve efficiency and avert pitfalls in therapeutic development.
At INVEST Precision Medicine, a look at the software behind biopharma R&D
The conference, set for June 9-11, will explore different aspects of precision medicine, including the software being used to support drug and therapeutic development.
Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
Research and Development: Bridging the Gap Between Hospitals, Patients, and Life Sciences
We live in a golden age of medicine. Never before have so many effective treatment options been available to so many people. And precision medicine is bringing new horizons, as well as the promise to further improve disease prevention, treatment, and ultimately find more cures. To keep moving toward personalized medicine approaches, more individuals would […]